Javier Arbizu

Jan 8, 2025 | alz-journals.onlinelibrary.wiley.com | Gil D. Rabinovici |Biomedical Imaging |David S. Knopman |Javier Arbizu

1 INTRODUCTION AND SCOPE Alzheimer's disease (AD) is defined neuropathologically by the deposition of extracellular plaques composed of aggregated forms of the amyloid-beta (Aβ) polypeptide and intraneuronal neurofibrillary tangles (NFTs) composed of aggregated hyperphosphorylated tau protein.1, 2 In the past 20 years, positron emission tomography (PET) radiotracers have been developed to image amyloid plaques and tau tangles in vivo.3-9 Currently, three fluorine-18-labeled amyloid...

Jan 7, 2025 | jnm.snmjournals.org | Gil D. Rabinovici |David S. Knopman |Javier Arbizu |Tammie L.S. Benzinger

Using the evidence summary, their clinical experience and expertise, and their knowledge of research outside of the scope of the evidence review, the workgroup used a modified Delphi approach to reach consensus on ratings for each of the clinical scenarios. This approach consisted of an online survey and 2 rounds of virtual scoring. When rating each scenario, workgroup members were asked to assess the benefits and risks to patients of using amyloid and tau PET imaging for the diagnosis of AD.